Method of inhibiting stenosis and restenosis
AssigneeMillennium Pharmaceuticals, Inc.
InventorsChristopher J. Horvath, Patricia E. Rao
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD18 or CCR2.
Claims5
A method of inhibiting stenosis or restenosis of a blood vessel following a vascular intervention procedure which includes the placement of a stent in a subject, comprising administering to said subject a therapeutically effective amount of a first therapeutic agent and a therapeutically effective amount of a second therapeutic agent, wherein
- said first therapeutic agent is an anti-CD18 antibody or antigen-binding fragment thereof which binds CD18 and inhibits binding of a ligand to an integrin which contains CD18, wherein said anti-CD18 antibody or antigen-binding fragment comprises light chain complementarity determining regions (CDR1, CDR2 and CDR3) of nonhuman origin, heavy chain complementarity determining regions (CDR1, CDR2 and CDR3) of nonhuman origin, and at least a portion of an immunoglobulin of human origin, wherein said light chain complementarity determining regions and said heavy chain complementarity determining regions have the amino acid sequences set forth below:
- light chain:
- CDR1:
- the amino acid sequence of SEQ ID NO:2
- CDR2:
- the amino acid sequence of SEQ ID NO:3
- CDR3:
- the amino acid sequence of SEQ ID NO:4
- heavy chain:
- CDR1:
- the amino acid sequence of SEQ ID NO:6
- CDR2:
- the amino acid sequence of SEQ ID NO:7
- CDR3:
- the amino acid sequence of SEQ ID NO:8;
- and
- said second therapeutic agent is an anti-CCR2 antibody or antigen-binding fragment thereof which binds CCR2 and inhibits binding of a ligand to said CCR2, wherein said anti-CCR2 antibody or antigen-binding fragment comprises light chain complementarity determining regions (CDR1, CDR2 and CDR3) of nonhuman origin, heavy chain complementarity determining regions (CDR1, CDR2 and CDR3) of nonhuman origin, and at least a portion of an immunoglobulin of human origin, wherein said light chain complementarity determining regions and said heavy chain complementarity determining regions have the amino acid sequences set forth below:
- light chain:
- CDR1:
- the sequence of amino acids 24-39 of SEQ ID NO:11
- CDR2:
- the sequence of amino acids 55-61 of SEQ ID NO:11
- CDR3:
- the sequence of amino acids 94-102 of SEQ ID NO:11
- heavy chain:
- CDR1:
- the sequence of amino acids 31-35 of SEQ ID NO:12
- CDR2:
- the sequence of amino acids 50-68 of SEQ ID NO:12
- CDR3:
- the sequence of amino acids 101-106 of SEQ ID NO:12.
Dependencies are inferred from the claim text.